Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

@article{Cannon2000OralGI,
  title={Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.},
  author={Christopher Paul Cannon and Carolyn H. McCabe and Robert G. Wilcox and Anatoly Langer and Avi Caspi and P Berink and Jos{\'e} Lu{\'i}s L{\'o}pez-Send{\'o}n and Jir{\'i} Toman and Andrew Charlesworth and Robert J. Anders and J. Craig Alexander and Allan Skene and Eugene Braunwald},
  journal={Circulation},
  year={2000},
  volume={102 2},
  pages={149-56}
}
BACKGROUND Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events. METHODS AND RESULTS Investigators at 888 hospitals in 29 countries enrolled 10 288 patients with acute coronary syndromes, which was defined as ischemic pain at rest within 72 hours of randomization, associated with positive cardiac markers, electrocardiographic changes, or prior… CONTINUE READING
80 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial.Lancet.2000;355:337–345

  • The SYMPHONY Investigators
  • 2000
1 Excerpt

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization.N Engl J Med2000;342:1316–1324

  • WW O’Neill, P Serruys, M Knudtson
  • 2000
1 Excerpt

Similar Papers

Loading similar papers…